One platform across disease boundaries
A platform organised around premature termination can generate reusable scientific knowledge across otherwise fragmented disease programmes.
Impact
A new translation platform.
Built to reach across diseases.
KritRNA’s long-term ambition is to transform a shared molecular failure into a family of programmable therapeutic opportunities—while creating durable scientific ownership and biotechnology capability from India.
India-owned scientific capability
Build company-owned computational, experimental and translational capability from the Indian biotechnology ecosystem.
Compounding experimental intelligence
Every well-designed experiment can improve future candidate selection, assay strategy and programme prioritisation.
Access-aware development from the beginning
Consider diagnosis, delivery, infrastructure and affordability while the technology is being built—not after it is finished.